{{Message}}

Utrecht, April 29, 2013

Mediq Suomi has acquired ILS Laboratories Scandinavia Oy, a Finnish distributor of clinical laboratory diagnostics. The products expand Mediq Suomi’s current laboratory product portfolio, strengthening Mediq’s leading market position in Finland.

ILS employs six people, who will join the Mediq office in Helsinki. ILS is specialised in 
sales, marketing and servicing of hemostasis (bleeding disorders) and other critical care 
diagnostic products in Finland and in Estonia. 

Marc van Gelder, CEO Mediq: “ILS is a perfect fit as Mediq already has a strong offering of clinical laboratory products in Finland and the Baltics. Mediq is a committed partner for healthcare professionals. We continue to expand our specialised product offering for hospitals, in order to support our customers in providing the best possible care to their patients.”

Utrecht, April 12, 2013

Mediq CombiCare acquires Hodes Medische Speciaalzaken. Hodes, a medical specialist business, supplies ostomy, incontinence and wound care products. It is a regional player based in Arnhem, with 20 employees. With this acquisition, Mediq CombiCare is strengthening its leading market position. 

Cristel Hodes, Director of Hodes: “We thought long and hard about this step. We want to retain our strong regional presence. That said, we also realise that we lack the economies of scale needed to meet the continually growing requirements of health insurers, which is why we’re joining Mediq CombiCare. They are a strong player in ostomy, incontinence and wound care, so we know for sure that, under the Mediq flag, our patients will still be in outstanding hands.” 
 
Marcel van den Broek, Executive Vice-President at Mediq: “We’re very pleased with this expansion in the Arnhem region. This acquisition fits in very well with our strategy for continued growth in the field of delivering medical devices for homecare. As such, we’d like to extend a warm welcome to our new colleagues.” 

Utrecht, February 13, 2013

Continuing growth for Direct & Institutional.

Financial highlights Q4 2012
Net sales − Down 3% to € 680.0 million; growth from acquisitions at D&I cancelled out by declining sales at Pharmacies Netherlands and Pharmacies Poland. 
EBITA from ordinary activities − Down 22% to € 29.0 million, mainly as a result of the declining sales from 
pharmaceuticals and the restructuring provision at Pharmacies Netherlands and higher corporate expenses. 
Net result − Amounted to € 10.0 million due to lower EBITA from ordinary activities and 
non-operational costs. 
Cash flow − Cash flow from operating activities of € 24.4 million. 
 
Operational highlights Q4 2012

Direct & Institutional
− Sales growth of 8% due to acquisitions; organic sales down by 1% following the transfer of biopharmaceuticals to the hospital budget (Netherlands). Excluding this effect, organic growth was 6%. 
− Positive trend in operating result for medical devices; lower operating result for pharmaceuticals (Netherlands). 
− EBITA margin from ordinary activities of 8.7%. 
− Acquisition of A-Med finalised; consolidated as of 1 December. 

Pharmacies Netherlands
− Lower sales and EBITA due to sharp fall in prices since beginning of 2012. 
− Restructuring of pharmacy and wholesaling activities; second tranche of restructuring provision recognised. 

Pharmacies Poland
− Sales down 10% as a result of a declining market since the beginning of 2012 due to statutory restrictions in patient discounts. 
− EBITA up, especially as result of higher gross margin and lower cost levels. 

Utrecht, February 12, 2013

99.7% of Shares tendered for acceptance - Delisting to occur on 13 March 2013 

AI Garden B.V. (the Offeror), a company ultimately indirectly controlled by funds advised and managed by Advent International Corporation (Advent), is pleased to announce that during the post closing acceptance period (na-aanmeldingstermijn) that ended on 12 February 2013 at 17:40 hours, Amsterdam time (the Post Closing Acceptance Period), 2,121,712 ordinary shares with a nominal value of EUR 0.25 each (the Shares) in the capital of Mediq N.V. (Mediq) were tendered for acceptance under the Offeror’s recommended all-cash public offer for all the issued and outstanding Shares (the Offer). These Shares represent approximately 3.6% of the total number of outstanding Shares and a value (at the increased Offer Price of EUR 14.00 per Share) of EUR 29,703,968.

Utrecht, February 04, 2013

Sjoerd van Keulen has decided to resign from Mediq’s Supervisory Board as per today. His decision is related to his recent media exposure. 

Mediq respects his decision and loses a dedicated chairman. Sjoerd van Keulen has been a member of the Supervisory Board since April 2010. He became chairman on 6 September 2010. 

Utrecht, February 01, 2013

Advent declares the public offer for all Shares in Mediq unconditional • More than 95% of the Shares tendered and accepted • Settlement will take place on 13 February 2013 • Remaining Shares can be tendered in a post acceptance period ending 12 February 2013 • Mediq to convene EGM

AI Garden B.V. (the Offeror), a company ultimately indirectly controlled by funds advised and managed by Advent International Corporation (Advent), is pleased to announce that it declares its recommended all-cash public offer (the Offer) for all the issued and outstanding ordinary shares with a nominal 
value of EUR 0.25 each (the Shares) in the capital of Mediq N.V. (Mediq) unconditional (doet gestand). 

Utrecht, January 29, 2013

With reference to Advent International's press release pursuant to Article 4 of the Decree on Public Takeover Bids (Besluit openbare biedingen Wft) dated today, Mediq, international supplier of medical devices and pharmaceuticals, informs that 96.1% of all issued and outstanding ordinary Mediq shares have been tendered to Advent International. 

The offer period, as extended by operation of law, ended today at 17:40 hours. Advent has informed that in total 96.1% of the Mediq shares have been tendered under the offer. At the latest on 1 February 2013, Advent will announce whether the offer for Mediq will be declared unconditional.

Utrecht, January 18, 2013

With reference to Advent International's press release pursuant to Article 15, paragraph 4 of the Decree on Public Takeover Bids (Besluit openbare biedingen Wft) dated today, Mediq informs that Advent has increased its public offer for all issued and outstanding ordinary shares in Mediq, launched on 8 November 2012, from € 13.25 per share to € 14.00 per share. 

The offer price of € 14.00 is final and will not be increased further. The offer price represents an increase of € 0.75 compared to the initial offer, representing a bid premium of 61.8% compared to the closing share price as at 21 September 2012, the day before the initial announcement. 
 
On 4 January 2013, Advent extended the offer period, which initially expired that day, by two weeks until 18 January 2013 17:40 hours. At that point in time, in aggregate approximately 54% of the Mediq shares had been tendered. Pursuant to the Decree on Public Takeover Bids (Besluit openbare biedingen Wft) the offer period of the offer will, in connection with this price increase, be extended with seven business days from the moment of the increase. As a result thereof, the offer period will expire on 29 January 2013 17.40 hours. 

Utrecht, January 07, 2013

With reference to the press release of Advent International (“Advent”) dated 4 January 2013 pursuant to the provision of Article 15, paragraph 2 of the Decree on Public Takeover Bids (Besluit openbare biedingen Wft), Mediq, international supplier of medical devices and pharmaceuticals, informs that Advent has extended the offer period for the public offer for all the issued and outstanding ordinary shares in the capital of Mediq by two weeks.

The initial offer period expired on 4 January 2013 at 17:40 hours CET. According to Advent, during the initial offer period in total around 54% of the shares has been tendered. The offer period has now been extended until 18 January 2013, 17:40 hours CET, such in accordance with the terms and conditions set out in the Offer Memorandum dated 8 November 2012. 

Mediq.com is using cookies

We use cookies to make Mediq websites easier to use, to deliver a personalised experience on our websites, and to better tailor our products, services and websites to your interests and needs.